Siemens Healthineers AG (SEMHF) Gets a Buy from Barclays

Barclays analyst Hassan Al-Wakeel maintained a Buy rating on Siemens Healthineers AG (SEMHFResearch Report) today and set a price target of EUR64.00. The company’s shares closed last Monday at $52.80.

According to TipRanks, Al-Wakeel is ranked #7438 out of 8007 analysts.

Siemens Healthineers AG has an analyst consensus of Strong Buy, with a price target consensus of $58.76, implying an 11.29% upside from current levels. In a report released on November 11, Societe Generale also maintained a Buy rating on the stock with a EUR57.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $77.35 and a one-year low of $38.66. Currently, Siemens Healthineers AG has an average volume of 1,018.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SEMHF in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Siemens Healthineers AG operates as a holding company. The company intends to operate the digital services business. It operates through the following business segments: Imaging, Diagnotics, and Advanced Therapies. The Imaging segment offers diagnostic imaging products and a broad portfolio of advanced imaging and ultrasound systems and solutions. The Diagnostics segment offers products, services and solutions, including a broad array of testing applications, in the areas of laboratory, point of care and molecular diagnostics. The Advanced Therapies is a supplier of advanced therapy products, services and solutions to the therapy departments of healthcare providers. Siemens Healthineers was founded on December 1, 2017 and is headquartered in Erlangen, Germany.

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More